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In this opinion piece we highlight the current concerns of prescribing antipsychotics to people 57 
with Learning Disability (PWLD) and propose a system of monitoring of antipsychotic 58 
prescribing in General Practice which we argue will reduce inappropriate antipsychotic use. 59 
Learning Disability, synonymous with the term intellectual disabilities (1) affects about 1-2% 60 
of the general population (2) and is characterized by significant impairments of both 61 
intellectual and adaptive functioning and an onset before 18. (3).  62 
PWLD have high rates of 'challenging behaviour’ (CB) - i.e., acts of aggression towards 63 
people or property, self-neglect, self-harm and the risk of exploitation (2). CB is a social 64 
construct to enumerate a behavioural or mental pattern that may cause suffering or a poor 65 
ability to function in life. It is best understood based on learning theory and the principles of 66 
applied behavioural analysis. Mental illness is a structured diagnostic concept which 67 
encompasses a large range of recognised emotional and behavioural disorders.  Mental 68 
illness diagnosis requires robust application of the diagnostic schedules. It is reasonable to 69 
state that most PWLD with mental illness have CB but majority of PWLD with CB might not 70 
satisfy criteria for mental illness. Therefore, the therapeutic approach to CB can be very 71 
different from a diagnostic one. However, there is significant overlap between CB and the 72 
presence of mental illnesses with the latter also being higher in PWLD than the general 73 
population. Deficits in communication, atypical clinical  presentations  and  differences  in74 
diagnostic coding methods mean that mental illness can be under-recorded, particularly in 75 
those with severe degrees of learning disability (1, 4).  This means that the clinician needs to 76 
be aware not just of what is observed behaviourally, but also whether there is something 77 
underlying diagnostically. A formulation based on both these elements is central to deciding 78 
whether there is a need to prescribe medication. 79 
The vast majority of PWLD with CB and/or mental illnesses are seen in primary care. There 80 
have been concerns that psychotropic medication is used inappropriately in this group to 81 
merely deal with the former (5). It is suggested that about 30-35000 PWLD are on 82 
antipsychotics or antidepressants or both without appropriate indications (6) and that the 83 
proportion of PWLD treated with psychotropic medication exceeds the proportion with 84 
recorded mental illness (7). NHS England has developed a national programme to stop over-85 
medication of PWLD (STOMP) (9).   The imperative should be to rationalise clinical practice 86 
by carefully balancing the need to stop unnecessary treatment with the possibility of under-87 
treatment that puts the patients or others at risk (1, 4).  88 
Though psychotropic medication can include antipsychotics, antidepressants, mood 89 
stabilisers, stimulants or anxiolytics, particular attention has been focused on antipsychotics. 90 
With recent data from secondary care, i.e- mental health services, suggesting that 91 
antipsychotics are not widely used outside of evidence-based indications in PWLD (8), there 92 
is a need to particularly focus on prescribing in primary care. 93 
In general for PWLD, there are 3 major circumstances in clinical practice which lead to 94 
antipsychotic prescribing; 95 
1. They have a mental illness with psychotic symptoms96 
2. They have CB97 
3. Both of the above98 
Only acceptable indication is psychosis for the longer term prescribing of anti-psychotics. 99 
The rationale for prescribing antipsychotics- either as a definitive diagnosis or as a narrative 100 
account of target symptoms has to be clearly recorded (4). This recording appears to be 101 
problematic in primary care. While 71% of those PWLD on antipsychotics did not have the 102 
diagnosis of a severe mental illness, the comparable figure for the general population though 103 
significantly lower was still 50% (7), suggesting that there is a need to improve the recording 104 
of the rationale for antipsychotic prescribing across the board. It is pertinent that in 105 
population studies, where ascertainment rates were recorded not just through primary care, 106 
the inappropriate prescribing rates for antipsychotics were found to be lower (10). 107 
The Royal College of Psychiatrists has published practice guidelines and four audit 108 
standards for prescribing these drugs (4) in PWLD. This includes clearly documenting the 109 
indication for prescribing, recording consent or best interests decision-making processes, 110 
regularly monitoring treatment response and side-effects and regularly reviewing the need 111 
for continuation based on risks and benefits. These four audit standards incorporate the 112 
NICE recommendation (11) that if antipsychotics are considered for behaviour that 113 
challenges, then it should be only used if psychological or other interventions alone have not 114 
produced change within an agreed time or treatment for any coexisting mental or physical 115 
health problem has not led to a reduction in the behaviour or the risk to the person or others 116 
is very severe. It also takes account of the NICE guidance ((1, 12) which recommended that: 117 
1. Prescribers should record full details of all medication including the doses, frequency and118 
purpose 119 
2. Record a summary of what information was provided about the medication prescribed to120 
the patient and carers 121 
3. Consider reducing or discontinuing antipsychotics for PWLD who are taking122 
antipsychotic drugs and not experiencing psychotic symptoms and then review their 123 
condition 124 
4. Annually document the reasons for continuing the prescription if it is not reduced or125 
discontinued    126 
5. Consider referral to a psychiatrist experienced in working with PWLD and mental health127 
problems. 128 
These recommendations and audit standards can pose a number of challenges in primary 129 
care. Firstly, there is the difficulty in changing a long established prescription that may have 130 
been the result of an inappropriate need (e.g. antipsychotic to manage acute distress), an 131 
appropriate but poorly recorded need (e.g. psychotic symptoms not recorded in patient 132 
notes), an unmet need (e.g. chronic social stressors) or resistance from carers, families and 133 
sometimes the patients themselves who may either see the medication as a ‘quick fix’ or 134 
genuinely feel that it has helped.  Secondly, many primary care prescriptions may well have 135 
started as part of recommendations from secondary care. However, ‘new ways of working’ 136 
where psychiatrists and mental health teams handle only “complex” patients while leaving 137 
routine follow up and care to primary care has resulted in a large population of people with 138 
learning disability who are on repeat prescriptions without review from or access to 139 
secondary care services, a group that can be described as the ‘vulnerable well’. Finally, any 140 
effort to change this status quo requires further resources to meet any unmet needs 141 
including access to psychology treatments, social care and other secondary care services.  142 
A range of views exist from primary care on how this problem needs to be tackled – 143 
1. A low threshold be present for referral to specialist teams to manage CB, but this144 
could potentially over-burden specialist services145 
2. The GP if identifying a mental illness initially prescribes and assess outcomes and146 
then refers if concerns persist. This however could lead to delay in specialised care147 
to a vulnerable adult.148 
3. If there is concern in the context of uncertain or no obvious co-morbid mental illness149 
to make a referral to specialist community team but this could potentially foster150 
diagnostic overshadowing.151 
To address the practicalities of this issue, there is a need for close working between primary 152 
and secondary care services involving GPs, community pharmacists, specialist learning 153 
disability teams and psychiatrists in learning disability. An  initiative is under way in Cornwall 154 
UK (pop: 550,000) with a pilot project involving all 64 GP practices, community pharmacists 155 
and specialist learning disability mental health teams to systematically stratify and reduce 156 
the level of antipsychotic prescribing. Using a computer program Eclipse, everyone who has 157 
a learning disability, but no other recorded mental illness and registered with a GP in 158 
Cornwall has been identified (n = 243). They are stratified from low risk to high risk based on 159 
the exposure to numbers and types of psychotropics with those on 2 antipsychotics being at 160 
the top (figure 1).  Assurance of baseline wellbeing is done using patient/carer held physical 161 
wellbeing records (13). To ensure the best possibility of success a STOMP-ID toolkit has 162 
been designed to provide assurance of rationalization and if necessary requirement of 163 
continuation of medication. Results of this pilot study will clarify the inputs, costs and efficacy 164 
of a programme to address this urgent issue that affects some of the most vulnerable people 165 
in society. The likelihood of there being a single way in which this current burden can be 166 
reduced is unlikely. Outcomes from such pilots are best placed to inform how to develop a 167 
unified strategy in future. 168 
169 
References 170 
1. National Institute for Health and Care Excellence. Mental Health Problems in People171 
with Learning Disabilities: Prevention, Assessment and Management. NG 54.172 
London: NICE, 2016. https://www.nice.org.uk/guidance/ng54 (accessed 15 Jan173 
2017).174 
2. Emerson E, Hatton C, Robertson J, Roberts H, Baines S, Glover G. People with175 
Learning Disabilities in England 2010. Improving Health and Lives: Learning176 
Disabilities Observatory, 2011.177 
http://www.improvinghealthandlives.org.uk/uploads/doc/vid_9244_IHAL2011-178 
02PWLD2010.pdf (accessed 15 Jan 2017).179 
3. World Health Organization. The ICD-10 classification of mental and behavioural180 
disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health181 
Organization, 1992.182 
4. Royal College of Psychiatrists. Psychotropic drug prescribing for people with183 
intellectual disability, mental health problems and/or behaviours that challenge:184 
practice guidelines. Faculty report FR/ID/09. London: Royal College of Psychiatrists,185 
2016. https://www.rcpsych.ac.uk/pdf/FR_ID_09_for_website.pdf (accessed 15 Jan186 
2017).187 
5. Department of Health. Department of Health Review: Winterbourne View Hospital188 
Interim Report. London: Department of Health, 2012.189 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/14159190 
1/Department-of-Health-Review-Winterbourne-View-Hospital-Interim-Report1.pdf191 
(accessed 15 Jan 2017).192 
6. Public Health England. Prescribing of Psychotropic Drugs to People with Learning193 
Disabilities and or Autism by General Practitioners in England. London: Public Health194 
England, 2015.195 
https://www.improvinghealthandlives.org.uk/securefiles/170115_1727//Psychotropic196 
%20medication%20and%20people%20with%20learning%20disabilities%20or%20aut197 
ism.pdf (accessed 15 Jan 2017).198 
7. Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L. Mental illness,199 
challenging behaviour, and psychotropic drug prescribing in people with intellectual200 
disability: UK population based cohort study. BMJ 2015 Sep 1;351:h4326.201 
8. Paton C, Bhatti S, Purandare K, Roy A, Barnes T. Quality of prescribing of202 
antipsychotic medication for people with intellectual disability under the care of UK203 
mental health services: a cross-sectional audit of clinical practice. BMJ Open 2016204 
Dec 5;6(12):e013116-2016-013116.205 
9. NHS England. Urgent action pledged on over-medication of people with learning206 
disabilities. Leeds: NHS England, 2015. https://www.england.nhs.uk/2015/07/urgent-207 
pledge/ (accessed 15 Jan 2017).208 
10. Bowring DL, Totsika V, Hastings RP. Prevalence of psychotropic medication use and209 
association with challenging behaviour in adults with an intellectual disability. A total210 
population study. J Intellect Disabil Res 2017, in press.211 
11. National Institute for Health and Care Excellence. Challenging Behaviour and212 
Learning Disabilities: Prevention and Interventions for People with Learning213 
Disabilities Whose Behaviour Challenges. NG11. London: NICE, 2015.214 
https://www.nice.org.uk/guidance/ng11 (accessed 15 Jan 2017).215 
12. National Institute for Health and Care Excellence. Learning Disabilities: Identifying216 
and managing mental health problems. QS142. London: NICE, 2017.217 
https://www.nice.org.uk/guidance/qs142 (accessed 15 Jan 2017).218 
13. Shankar R, Bradley-Smith G, Brigham P, Devapriam J, Osborne A, Axby S. Patient- 219 
and carer-held health records: can they improve annual health checks for patients220 
with learning disability? Br J Gen Pract 2016 Apr;66(645):210-212.221 
222 
Figure 1: - Risk stratification table for STOMP – ID Cornwall 
